ScholarIQanswers from OpenAlex & ORCID
Ho Yeong Lim
ResearcherPublications, citations & collaboration network
Ho Yeong Lim is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ho Yeong Lim have?
ScholarIQindexed works
Ho Yeong Lim has 591 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ho Yeong Lim have?
ScholarIQcitation count
Ho Yeong Lim has 40,306 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ho Yeong Lim?
ScholarIQh-index
Ho Yeong Lim has an h-index of 79 in OpenAlex.
What is the i10-index of Ho Yeong Lim?
ScholarIQi10-index
Ho Yeong Lim has an i10-index of 287 in OpenAlex.
What is the ORCID of Ho Yeong Lim?
ScholarIQorcid
The ORCID for Ho Yeong Lim is on the source record.
What is the OpenAlex record for Ho Yeong Lim?
ScholarIQopenalex
The OpenAlex for Ho Yeong Lim is on the source record.
What are the most-cited papers on Ho Yeong Lim?
ScholarIQmost cited works
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Eric Assénat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep M. Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Gianluca Masi, Mariusz Kwiatkowski, Ho Yeong Lim, Jee Hyun Kim, В. В. Бредер, Hiromitsu Kumada, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Anran Wang, Kalgi Mody, Corina E. Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Simone I. Strasser, Alexander Thompson, Aflah Roohullah, William Sievert, Vladimir Andelkovic, Jennifer J. Knox, Janine M. Davies, Jamil Asselah, Mayur Brahmania, Habeeb Majeed, Luis J. Villanueva-Rivera, Patricio Yañez Weber, Marcelo Garrido, Gonzalo Pizarro, Nicolás Yáñez, Ruocai Xu, Shuangyan Ou, Zhenggang Ren, Hongming Pan, Zhiqiang Meng, Kangsheng Gu, Xi Chen, Tao Zhang, Chunyi Hao, Peiguo Cao, Yabing Guo, Shukui Qin, Juxiang Xiao, Weijia Fang, Xin Wang, Yuxian Bai, Xiaoming Chen, Dong Yan, Hong Zhao, Jieer Ying, Carlos Bonilla, Olga Urrego, Ángela R. Zambrano, Mauricio Lema, Juan Carlos Restrepo, Andrés F. Cardona, Sandra Franco Millan, Madiedo Oscar, Víctor Ramos, Philippe Merle, Samuel Lesourd, Julien Edeline, Jean–Pierre Bronowicki, Marc Bourlière, Stéphane Cattan, Mohamed Bouattour, Laurent Mineur, Hélène Regnault, Barbara Dauvois, Kornelius Schulze, Gunnar Folprecht, Andreas Geier, Oliver Waidmann, Fabian Finkelmeier, Marino Venerito, Marie‐Luise Berres, Thomas Berg, Christian M. Lange, Hartmut Schmidt, Dirk Waldschmidt, Michael Bitzer, Ray McDermott, Austin G. Duffy, Gianluca Masi, Vittorina Zagonel, Giuseppe Tonini, Fabio Piscaglia, Stefania Gori, Mimma Rizzo, Elisa Biscaldi
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
L.-T. Chen, Erika Martinelli, Ann‐Lii Cheng, George Pentheroudakis, Si-bei Qin, G.S. Bhattacharyya, Masafumi Ikeda, Ho Yeong Lim, Gwo Fuang Ho, Su Pin Choo, Zhenggang Ren, Hemant Malhotra, Makoto Ueno, Baek‐Yeol Ryoo, Tina Kiang, David Tai, Arndt Vogel, Andrés Cervantes, Sheng‐Nan Lu, Chung‐Jen Yen, Yi‐Hsiang Huang, San‐Chi Chen, Chiun Hsu, Ying‐Chun Shen, Josep Tabernero, Yun Yen, Chih‐Hung Hsu, Takayuki Yoshino, J.-Y. Douillard